All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F16%3A10324861" target="_blank" >RIV/00064203:_____/16:10324861 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11130/16:10324861

  • Result on the web

    <a href="http://dx.doi.org/10.5507/bp.2016.029" target="_blank" >http://dx.doi.org/10.5507/bp.2016.029</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.5507/bp.2016.029" target="_blank" >10.5507/bp.2016.029</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up

  • Original language description

    Aims. Ivacaftor is a revolutionary treatment option for cystic fibrosis (CF) patients with G551D and other gating mutations. The aim of this study was to evaluate the clinical status of patients on ivacaftor who were followed for up to 6 years together with an evaluation of ivacaftor therapy in one patient with an initial FEV1 less than 40% of predicted value. Methods. Data on development of clinical status and sinopulmonary-related therapies were obtained from patient health records during ivacaftor treatment lasting for up to six years and were compared with an equivalent period before ivacaftor administration. Results. Five CF adults with a median age 28.6 years (range 21.4-35.6 years) with median FEV1 45% pred. (range 16-85% pred.) were included in the study. Four subjects were also participants in the STRIVE and PERSIST studies. Altogether, twenty-four patient-years of ivacaftor treatment were analyzed. The median FEV1 decline per year decreased from -4.5 to -0.9% pred. (P = 0.043). Reduction in number of days on antibiotic treatment and hospital stays was 21% (P < 0.001) and 75% (P = 0.003), respectively. Improvement and stabilization of lung function was observed for up to six years of treatment. In a patient with severe airway obstruction, an increase in the FEV1 value (30.4% from baseline) was documented during the first twelve months of treatment. Conclusion. Ivacaftor therapy resulted in improved and stabilized lung function in up to six years of treatment with a reduction in number of days on antibiotic treatment and hospital stays. Its efficiency was also displayed in a patient with severe airway obstruction.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FC - Pneumology

  • OECD FORD branch

Result continuities

  • Project

    <a href="/en/project/LD14073" target="_blank" >LD14073: Implementation of next generation sequencing in CZ: ethical and clinical genetic indication issues</a><br>

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Biomedical Papers

  • ISSN

    1213-8118

  • e-ISSN

  • Volume of the periodical

    160

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    CZ - CZECH REPUBLIC

  • Number of pages

    4

  • Pages from-to

    276-279

  • UT code for WoS article

    000379360500015

  • EID of the result in the Scopus database

    2-s2.0-84976344716